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Changes in Serum Testosterone after 
Bilateral Orchiectomy in Patients with 
Metastatic Carcinoma of the Prostate 
Richard Senn, M D * , Riad Farah, M D * * , Julius O h o r o d n i k , M D * * * & Joseph C. Cerny, M D * 
From a study of 38 patients. It may be 
concluded that, first, changes In serum tes-
tosterone levels of patients undergoing or-
chiectomy for metastatic carcinoma of the 
prostate are unrelated to the clinical course 
of the patient; second, no clear correlation 
exists between quantitative Leydig cell 
counts and levels of plasma testosterone; 
and, third, exacerbation of metastatic dis-
ease is observed while plasma testosterone 
remains in the castrate range. These observa-
tions question the exact function of the 
Leydig cell and Its role In androgen produc-
tion, and indicate that prostatic neoplasms 
have varying degrees of response to reduced 
androgen levels and/or androgen-IIke sub-
stances following castration. 
H o r m o n a l treatment of patients with meta-
static prostatic carcinoma has been directed 
at lowering androgen production by the 
testes. Generally, this decrease in androgen 
production has been assessed by measure-
ment of total urinary 17-keto steroid and/or 
individual urinary androgen metabolites. 
Recent studies indicate that such determina-
tions are of limited value since the steroids 
measured are derived from both adrenal and 
gonadal precursors, some of wh ich are 
weakly androgenic, or even nonandrogenic. 
Plasma testosterone measurement offers a 
more direct approach to the study of tumor 
androgen relationships since it is the most 
potent androgen secreted. Seventy percent 
of testosterone measured in plasma in men 
arises from the testes. The present study was 
designed to evaluate the relat ionship of 
plasma testosterone levels to the clinical 
response of patients undergoing bilateral 
orchiectomy for metastatic carcinoma of the 
prostate. 
* N o w in private practice in Kokomo, IN 
** Division of Urology, Department of Surgery 
*** Department of Pathology 
Address reprint requests to Dr. Cerny at Henry 
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troit Ml 48202 
Mater ia ls and methods 
Thirty-eight men with proven carcinoma 
of the prostate and symptomatic bony meta-
stases were treated with bilateral therapeutic 
orchiectomy. Immediate preoperative and 
three-day postoperative serum testosterone 
levels were determined. Correlations were 
made between a) preoperative testosterone 
levels, b) fall in postoperative testosterone 
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levels, c) acid and alkaline phosphatase, d) 
testicular-Leydig cell counts, and e) pres-
enceorabsence and length of clinical symp-
tomatic improvement. 
Quantitative Leydig cell determinations 
were made by countingthe actual number of 
Leydig cells and seminiferous tubules in 100 
random fields of each testis, then averaging 
the number of Leydig cells per seminiferous 
tubule. 
The method of plasma testosterone deter-
mination is that modified from Kato and 
Hortens, u t i l i z ing compet i t ive protein 
binding. 
Results 
Plasma testosterone, measured mug/100/ 
ml plasma, ranged from 110 to 1404 (mean 
506), prior to orchiectomy, and fell from 12 
to 187 (mean 64), postoperatively. The aver-
age postoperative testosterone determina-
tion was 15% of its preoperative level. 
Plasma acid phosphatase, measured in 
King-Armstrong units, ranged from 4 to 317 
(mean 39), prior to orchiectomy, and fell to 
from 2 to 54 (mean 10), postoperatively. The 
average postoperative acid phosphatase was 
25% of its preoperative level. 
Leydig cell counts, eg, number of Leydig 
cells per seminiferous tubule, showed grad-
ual reduction with increasing patient age. 
Average numberof Leydigcells was seven in 
the age group 30-39, and decreased to three 
in the age group 65-75. 
Thirty-six of 38 patients undergoing or-
chiectomy noted immediate relief of osseous 
pain. W i t h i n six months of operat ion, 
however, 32 of the 36 noted recurrence of 
varying degrees of pain, as well as other 
stigmata of metastatic disease. 
No significant correlation was observed 
between (a) preoperative testosterone levels 
and Leydig cell counts, (b) ratio of post-
operative/ preoperative testosterone and de-
gree and duration of remission of symptoms, 
(c) ratio of postoperative/preoperative acid 
phosphatase and degree of duration of re-
mission of symptoms, or (d) clinical response 
in patients having we l l d i f ferent iated vs 
poorly differentiated adenocarcinoma of the 
prostate. 
Clinical exacerbation of metastases fol-
lowing initial remission, manifested by re-
current pain, progressive osseous involve-
ment and increasing levels of acid phos-
phatase activity, was not accompanied by 
increase in plasma testosterone, which re-
mained in the castrate range. 
Discussion and Conclusion 
It was distressing to observe that while 36 
of 38 patients had excellent immediate relief 
of metastatic pain followingorchiectomy, all 
but four noted varyingdegrees of recurrence 
within six months postoperatively. While 
prompt decrease in plasma testosterone fol-
lowed orchiectomy, that decrease was nei-
ther related to Leydig cell counts or degree 
and duration of remission of symptoms. Of 
further interest was the observat ion that 
plasma testosterone remained in the castrate 
range in the face of recurrent activity of the 
neoplasm, and response to orchiectomy was 
unrelated to tumor grade. 
The poor response to orchiectomy seen in 
many patients may represent a) a marginal 
and transient tumor androgen dependence, 
b) hypersensitivity to minute amounts of 
adrenal androgen, eg, androstanedione 
which is convertible to testosterone, or c) 
nonandrogenic factors s t imulat ing the 
neoplasm. 
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